NCT05845645View on ClinicalTrials.gov

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

April 13, 2024

Study Completion Date

April 13, 2024

Conditions
Healthy Study Participants
Interventions
DRUG

UCB0599

Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B

OTHER

Esomeprazole

Study participants will receive fixed dose of esomeprazole administered orally in a pre-specified sequence during the Treatment Period of Part A. This is a non-investigational medicinal product (NIMP) in this study.

OTHER

Placebo

Study participants will receive placebo comparator administered orally in a a pre-specified sequence during the Treatment Period of Part B.

Trial Locations (1)

91206

Up0073 10001, Glendale

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT05845645 - A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B | Biotech Hunter | Biotech Hunter